Akel Homes Demonstrates Enthusiastic Support as Silver Benefactor for the 2024 LLS Black Tie Gala, Eager to Contribute to Life-Saving Cancer Research
Akel Homes proudly announces its support to the Leukemia & Lymphoma Society (LLS) as a Silver Benefactor sponsor of this year's Dare to Disco Black Tie Gala hosted at The Breakers, Palm Beach on January 24th. PALM BEACH, Fla., Feb. 2, 2024 /PRNewswire-PRWeb/ -- The 2024 Dare to Disco Gala... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 2, 2024 Category: Pharmaceuticals Tags: SVY NPT Source Type: news
Camp Lejeune Water Contamination Tied to a Range of Cancers
NEW YORK — Military personnel stationed at Camp Lejeune from 1975 to 1985 had at least a 20% higher risk for a number of cancers than those stationed elsewhere, federal health officials said Wednesday in a long-awaited study about the North Carolina base’s contaminated drinking water.
Federal health officials called the research one the largest ever done in the United States to assess cancer risk by comparing a group who live and worked in a polluted environment to a similar group that did not.
[time-brightcove not-tgx=”true”]
The study found military personnel stationed at U.S. Marine Corps ...
Source: TIME: Health - February 1, 2024 Category: Consumer Health News Authors: Mike Stobbe/AP Tags: Uncategorized healthscienceclimate wire Source Type: news
Adolescent and Young Adult (AYA) Cancer Experts Unite to Form First-of-its-Kind Consortium
World-Renowned Hematologist/Oncologists to Lead Executive Committee Dedicated to Improving the Field of Adolescent and Young Adult Lymphoma Research and Patient Care NEW YORK, Jan. 30, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 30, 2024 Category: Pharmaceuticals Source Type: news
Fight Your Blood Cancer: Early CAR NK Therapy Clinical Results
A novel cancer treatment using natural killer cells produces encouraging results in people with certain leukemias and lymphomas. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 29, 2024 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Doctor shares eight warning signs of Hodgkin's lymphoma cancer to look out for
From night sweats to itchy skin, a medical expert has issued advice about the symptoms of a blood cancer as getting checked early could save lives. (Source: Daily Express - Health)
Source: Daily Express - Health - January 28, 2024 Category: Consumer Health News Source Type: news
Mayo Clinic Minute: How precise diagnosis of lymphoma offers patients best treatment options
Dr. Lisa Rimsza is a pathologist, director of the Mayo Clinic Molecular Diagnostic Laboratory and researcher with the Mayo Clinic Comprehensive Cancer Center. Her research specializes in lymphoma, with a focus on developing tests for accurate patient diagnoses and assessing disease aggressiveness. Dr. Rimsza has made significant advances in this field of research. She says having a precise diagnosis allows physicians to provide patients with the best possible treatment. Watch: The Mayo Clinic Minute https://youtu.be/M6ARKpwlWYU Journalists: Broadcast-quality video pkg (1:05) is in&h...
Source: News from Mayo Clinic - January 26, 2024 Category: Databases & Libraries Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news
You Can ’t Have Healthy People On a Sick Planet
About a year ago, I was declared cancer-free after four months of chemotherapy at Providence St. John’s Health Center in Santa Monica, Calif. I had been diagnosed with low-grade B cell non-Hodgkin Lymphoma. This was not my first encounter with cancer. I’d had breast cancer a number of years prior, which was treated with radiation and then a full mastectomy. I realize I’m lucky. I had caring, attentive doctors and nurses who saved my life. I also realize how much progress has been made in cancer research and I am deeply grateful.
[time-brightcove not-tgx=”true”]
Yet despite that, cancer has...
Source: TIME: Health - January 12, 2024 Category: Consumer Health News Authors: Jane Fonda Tags: Uncategorized climate change Climate Is Everything Source Type: news
Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma
(MedPage Today) -- Treatment with single-agent pirtobrutinib (Jaypirca), a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 11, 2024 Category: Hematology Source Type: news
Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T
(MedPage Today) -- A phase Ib/II study demonstrated that mosunetuzumab (Lunsumio) plus polatuzumab vedotin (Polivy) induced durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL), including patients who relapsed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 11, 2024 Category: Hematology Source Type: news
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and…#nih #vincerx #paloalto #vincerxpharma #cdk9 #ahmedhamdy #nonhodgkin #ianflinn #phd #vip236 (Source: Reuters: Health)
Source: Reuters: Health - January 7, 2024 Category: Consumer Health News Source Type: news
Why Is Cell Therapy Focused Allogene Therapeutics (ALLO) Stock Trading Lower Today?
Allogene Therapeutics Inc ALLO announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal trial (ALPHA3) evaluating cema-cel as a consolidation therapy in large B-cell lymphoma (LBCL) patients in…#phase2alpha2 #expand #alpha3 #alpha2 #cll #dagger #foresightdiagnostics #mrd #ivd #williamblair (Source: Reuters: Health)
Source: Reuters: Health - January 5, 2024 Category: Consumer Health News Source Type: news
Liso-Cel Cost-Effective for Second-Line Relapsed/Refractory Lymphoma
THURSDAY, Jan. 4, 2024 -- Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2024 Category: Pharmaceuticals Source Type: news
Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients
(MedPage Today) -- Durable responses were seen when axicabtagene ciloleucel (axi-cel; Yescarta) was administered as a first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), according to findings from the phase II ZUMA-12 trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 4, 2024 Category: Hematology Source Type: news
